201: ADX-038 in Kidney Disease

• Research type

  Research Study

• Full title

  A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

• IRAS ID

  1012313

• Contact name

  Christopher Claeboe

• Contact email

  cclaeboe@adarx.com

• Sponsor organisation

  ADARx Pharmaceuticals, Inc.

• Eudract number

  2025-521752-26

• Clinicaltrials.gov Identifier

  NCT06989359

• Research summary

  ADX-038 is a type of therapy called small interfering RNA (siRNA), which works by blocking the production of CFB in the liver; it does not change your DNA. By reducing complement factor B (CFB) levels, ADX-038 is expected to decrease overactivation of the complement system, which may help reduce inflammation and kidney damage. This phase 2 study will help determine whether ADX-038, specifically, 4 injections given 3 months apart, under the skin (subcutaneous) is safe, and whether lowering CFB can have a positive effect on kidney disease.

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  25/LO/0853

• Date of REC Opinion

  6 Jan 2026

• REC opinion

  Further Information Favourable Opinion